导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 0.85% | 2165/4773 |
| 近一周 | -1.75% | 1561/5458 |
| 近一月 | -3.23% | 1950/5421 |
| 近一季 | -3.70% | 2068/5205 |
| 近半年 | -1.33% | 1789/4920 |
| 近一年 | 3.38% | 2087/4361 |
| 近两年 | 50.50% | 1469/2954 |
| 近三年 | 31.77% | 991/2253 |
| 成立以来 | 78.37% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.82% 2924/4961 |
12.90% 2097/5312 |
- - |
- - |
| 2025 | 20.78% 2092/4813 |
-0.53% 2285/3635 |
2.07% 1895/4076 |
18.40% 2305/4524 |
0.46% 1986/4813 |
| 2024 | 15.54% 914/3463 |
2.62% 739/2808 |
-1.27% 1014/3014 |
15.62% 1673/3129 |
-1.37% 1670/3463 |
| 2023 | -8.68% 1043/2656 |
3.85% 1109/2280 |
-4.55% 1200/2385 |
-2.43% 676/2515 |
-5.57% 1403/2655 |
| 2022 | -16.97% 537/2207 |
-13.55% 780/1919 |
7.50% 463/2016 |
-11.99% 624/2113 |
1.53% 1234/2208 |
| 2021 | 5.75% 536/1822 |
-2.37% 631/1255 |
8.73% 606/1330 |
-2.63% 586/1466 |
2.32% 624/1822 |
| 2020 | 43.40% 245/1250 |
-5.77% 437/1028 |
16.50% 434/1067 |
14.18% 295/1164 |
14.40% 278/1184 |
| 2019 | - - |
- - |
-1.08% 287/788 |
1.55% 390/850 |
7.56% 423/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 易方达MSCI中国A股联接A VS. 长安沪深300非周期A(740101) |